Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas: A review

World Journal of Gastroenterology

Volumn 21, Issue 26, 2015, Pages 8014-8020

  Asano, Naoki ^a   Iijima, Katsunori ^a   Koike, Tomoyuki ^a   Imatani, Akira ^a   Shimosegawa, Tooru ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antibiotics; API2 MALT1; Endoscopy; Helicobacter pylori; Mucosa associated lymphoid tissue lymphoma

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR; TUMOR MARKER;

ANTIBIOTIC THERAPY; CANCER PATIENT; ERADICATION THERAPY; HELICOBACTER PYLORI; HUMAN; MAGNIFYING ENDOSCOPY; MARGINAL ZONE LYMPHOMA; NARROW BAND IMAGING; PROTEIN SYNTHESIS; REVIEW; TREATMENT RESPONSE; ANIMAL; COMPLICATION; DRUG EFFECTS; GASTROSCOPY; GENETIC PREDISPOSITION; GENETICS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; LYMPHOMA, B-CELL, MARGINAL ZONE; METABOLISM; MICROBIOLOGY; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOMARKERS, TUMOR; GASTROSCOPY; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTON PUMP INHIBITORS; RISK FACTORS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84936998649     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i26.8014     Document Type: Review

References (60)

1. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410-1416 [PMID: 6193858]
2. Nakamura S, Matsumoto T. Helicobacter pylori and gastric mucosa-associated lymphoid tissue lymphoma: recent progress in pathogenesis and management. World J Gastroenterol 2013; 19: 8181-8187 [PMID: 24363507 DOI: 10.3748/wjg.v19.i45.8181]
3. Nakamura S, Matsumoto T, Ye H, Nakamura S, Suekane H, Matsumoto H, Yao T, Tsuneyoshi M, Du MQ, Iida M. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma: a clinicopathologic and molecular study with reference to antibiotic treatment. Cancer 2006; 107: 2770-2778 [PMID: 17099876 DOI: 10.1002/cncr.22326]
4. Raderer M, Streubel B, Wöhrer S, Häfner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616-618 [PMID: 16299027 DOI: 10.1136/gut.2005.083022]
5. Lahner E, Milione M, Delle Fave G, Annibale B. H. pylori negative MALT lymphoma patients successfully treated with antibiotics: doubts about their H. pylori negativity. Gut 2006; 55: 1669; author reply 1669 [PMID: 17047118]
6. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, Tari A, Kitadai Y, Matsumoto H, Nagaya T, Kamoshida T, Watanabe N, Chiba T, Origasa H, Asaka M. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-513 [PMID: 21890816 DOI: 10.1136/gutjnl-2011-300495]
7. Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lymphoma: old and new insights. Ann Gastroenterol 2014; 27: 27-33 [PMID: 24714739]
8. Greiner A, Knörr C, Qin Y, Sebald W, Schimpl A, Banchereau J, Müller-Hermelink HK. Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation. Am J Pathol 1997; 150: 1583-1593 [PMID: 9137085]
9. Craig VJ, Arnold I, Gerke C, Huynh MQ, Wündisch T, Neubauer A, Renner C, Falkow S, Müller A. Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins. Blood 2010; 115: 581-591 [PMID: 19965661 DOI: 10.1182/blood-2009-06-228015]
10. Munari F, Lonardi S, Cassatella MA, Doglioni C, Cangi MG, Amedei A, Facchetti F, Eishi Y, Rugge M, Fassan M, de Bernard M, D'Elios MM, Vermi W. Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. Blood 2011; 117: 6612-6616 [PMID: 21527528 DOI: 10.1182/blood-2010-06-293266]
11. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia 2007; 21: 389-396 [PMID: 17230229 DOI: 10.1038/sj.leu.2404517]
12. Nakamura S, Ye H, Bacon CM, Goatly A, Liu H, Banham AH, Ventura R, Matsumoto T, Iida M, Ohji Y, Yao T, Tsuneyoshi M, Du MQ. Clinical impact of genetic aberrations in gastric MALT lymphoma: a comprehensive analysis using interphase fuorescence in situ hybridisation. Gut 2007; 56: 1358-1363 [PMID: 17525089 DOI: 10.1136/gut.2007.123729]
13. Nakamura S, Matsumoto T, Nakamura S, Jo Y, Fujisawa K, Suekane H, Yao T, Tsuneyoshi M, Iida M. Chromosomal translocation t(11; 18)(q21; q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol 2003; 56: 36-42 [PMID: 12499431]
14. Ye H, Liu H, Raderer M, Chott A, Ruskone-Fourmestraux A, Wotherspoon A, Dyer MJ, Chuang SS, Dogan A, Isaacson PG, Du MQ. High incidence of t(11; 18)(q21; q21) in Helicobacter pylori-negative gastric MALT lymphoma. Blood 2003; 101: 2547-2550 [PMID: 12517817 DOI: 10.1182/blood-2002-10-3167]
15. Motegi M, Yonezumi M, Suzuki H, Suzuki R, Hosokawa Y, Hosaka S, Kodera Y, Morishima Y, Nakamura S, Seto M. API2-MALT1 chimeric transcripts involved in mucosa-associated lymphoid tissue type lymphoma predict heterogeneous products. Am J Pathol 2000; 156: 807-812 [PMID: 10702396 DOI: 10.1016/S0002-9440(10)64948-6]
16. Akagi T, Motegi M, Tamura A, Suzuki R, Hosokawa Y, Suzuki H, Ota H, Nakamura S, Morishima Y, Taniwaki M, Seto M. A novel gene, MALT1 at 18q21, is involved in t(11; 18) (q21; q21) found in low-grade B-cell lymphoma of mucosa-associated lymphoid tissue. Oncogene 1999; 18: 5785-5794 [PMID: 10523859]
17. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, De Wolf-Peeters C, Hagemeijer A, Van den Berghe H, Marynen P. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11; 18)(q21; q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood 1999; 93: 3601-3609 [PMID: 10339464]
18. Rosebeck S, Madden L, Jin X, Gu S, Apel IJ, Appert A, Hamoudi RA, Noels H, Sagaert X, Van Loo P, Baens M, Du MQ, Lucas PC, McAllister-Lucas LM. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 2011; 331: 468-472 [PMID: 21273489 DOI: 10.1126/science.1198946]
19. Zhou H, Du MQ, Dixit VM. Constitutive NF-kappaB activation by the t(11; 18)(q21; q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005; 7: 425-431 [PMID: 15894263 DOI: 10.1016/j.ccr.2005.04.012]
20. Lucas PC, Kuffa P, Gu S, Kohrt D, Kim DS, Siu K, Jin X, Swenson J, McAllister-Lucas LM. A dual role for the API2 moiety in API2-MALT1-dependent NF-kappaB activation: heterotypic oligomerization and TRAF2 recruitment. Oncogene 2007; 26: 5643-5654 [PMID: 17334391 DOI: 10.1038/sj.onc.1210342]
21. Rosebeck S, Rehman AO, Apel IJ, Kohrt D, Appert A, O'Donnell MA, Ting AT, Du MQ, Baens M, Lucas PC, McAllister-Lucas LM. The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-κB signaling. Oncogene 2014; 33: 2520-2530 [PMID: 23770847 DOI: 10.1038/onc.2013.195]
22. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18: 19-26 [PMID: 18440219 DOI: 10.1016/j.gde.2008.01.020]
23. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432 [PMID: 10643532]
24. Morgner A, Lehn N, Andersen LP, Thiede C, Bennedsen M, Trebesius K, Neubauer B, Neubauer A, Stolte M, Bayerdörffer E. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-828 [PMID: 10784580]
25. O'Rourke JL, Dixon MF, Jack A, Enno A, Lee A. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma in an animal model of 'Helicobacter heilmannii' infection. J Pathol 2004; 203: 896-903 [PMID: 15258991 DOI: 10.1002/path.1593]
26. Nocturne G, Mariette X. Sjögren Syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol 2015; 168: 317-327 [PMID: 25316606 DOI: 10.1111/bjh.13192]
27. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005; 165: 2337-2344 [PMID: 16287762 DOI: 10.1001/archinte.165.20.2337]
28. Aozasa K. Hashimoto's thyroiditis as a risk factor of thyroid lymphoma. Acta Pathol Jpn 1990; 40: 459-468 [PMID: 2220394]
29. Hu C, Yi C, Dai X. Clinical study of 31 patients with primary gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol 2006; 21: 722-726 [PMID: 16677159 DOI: 10.1111/j.1440-1746.2006.04249.x]
30. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH, Megraud F, Palazzo L, de Mascarel A, Molina T, Rambaud JL. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001; 48: 297-303 [PMID: 11171816]
31. Nakamura S, Yao T, Aoyagi K, Iida M, Fujishima M, Tsuneyoshi M. Helicobacter pylori and primary gastric lymphoma. A histopathologic and immunohistochemical analysis of 237 patients. Cancer 1997; 79: 3-11 [PMID: 8988720]
32. Isomoto H, Matsushima K, Hayashi T, Imaizumi Y, Shiota J, Ishii H, Minami H, Ohnita K, Takeshima F, Shikuwa S, Miyazaki Y, Nakao K. Endocytoscopic fndings of lymphomas of the stomach. BMC Gastroenterol 2013; 13: 174 [PMID: 24369830 DOI: 10.118 6/1471-230X-13-174]
33. Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001; 48: 454-460 [PMID: 11247887]
34. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577 [PMID: 8102719]
35. Fischbach W. Gastric MALT lymphoma-update on diagnosis and treatment. Best Pract Res Clin Gastroenterol 2014; 28: 1069-1077 [PMID: 25439072 DOI: 10.1016/j.bpg.2014.09.006]
36. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, Montalban C, Raderer M, Savio A, Wotherspoon A. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut 2011; 60: 747-758 [PMID: 21317175 DOI: 10.1136/gut.2010.224949]
37. Rohatiner A, d'Amore F, Coiffer B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M. Report on a workshop convened to discuss the pathological and staging classifcations of gastrointestinal tract lymphoma. Ann Oncol 1994; 5: 397-400 [PMID: 8075046]
38. Lopes AI, Vale FF, Oleastro M. Helicobacter pylori infection-recent developments in diagnosis. World J Gastroenterol 2014; 20: 9299-9313 [PMID: 25071324 DOI: 10.3748/wjg.v20.i28.9299]
39. Boeriu A, Boeriu C, Drasovean S, Pascarenco O, Mocan S, Stoian M, Dobru D. Narrow-band imaging with magnifying endoscopy for the evaluation of gastrointestinal lesions. World J Gastrointest Endosc 2015; 7: 110-120 [PMID: 25685267 DOI: 10.4253/wjge.v7.i2.110]
40. Nonaka K, Ishikawa K, Arai S, Nakao M, Shimizu M, Sakurai T, Nagata K, Nishimura M, Togawa O, Ochiai Y, Sasaki Y, Kita H. A case of gastric mucosa-associated lymphoid tissue lymphoma in which magnifed endoscopy with narrow band imaging was useful in the diagnosis. World J Gastrointest Endosc 2012; 4: 151-156 [PMID: 22523617 DOI: 10.4253/wjge.v4.i4.151]
41. Nonaka K, Ohata K, Matsuhashi N, Shimizu M, Arai S, Hiejima Y, Kita H. Is narrow-band imaging useful for histological evaluation of gastric mucosa-associated lymphoid tissue lymphoma after treatment? Dig Endosc 2014; 26: 358-364 [PMID: 24118642 DOI: 10.1111/den.12169]
42. Fischbach W. MALT lymphoma: forget surgery? Dig Dis 2013; 31: 38-42 [PMID: 23797121 DOI: 10.1159/000347176]
43. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2013; 24: 16-19 [PMID: 22877993 DOI: 10.1016/j.ejim.2012.07.006]
44. Miftahussurur M, Yamaoka Y. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules 2015; 20: 6068-6092 [PMID: 25856059 DOI: 10.3390/molecules20046068]
45. Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999; 131: 88-95 [PMID: 10419446]
46. Akamatsu T, Mochizuki T, Okiyama Y, Matsumoto A, Miyabayashi H, Ota H. Comparison of localized gastric mucosa-associated lymphoid tissue (MALT) lymphoma with and without Helicobacter pylori infection. Helicobacter 2006; 11: 86-95 [PMID: 16579838 DOI: 10.1111/j.1523-5378.2006.00382.x]
47. Terai S, Iijima K, Kato K, Dairaku N, Suzuki T, Yoshida M, Koike T, Kitagawa Y, Imatani A, Sekine H, Ohara S, Shimosegawa T. Long-term outcomes of gastric mucosa-associated lymphoid tissue lymphomas after Helicobacter pylori eradication therapy. Tohoku J Exp Med 2008; 214: 79-87 [PMID: 18212490]
48. Park HS, Kim YJ, Yang WI, Suh CO, Lee YC. Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 2010; 16: 2158-2162 [PMID: 20440857]
49. Asano N, Iijima K, Terai S, Jin X, Ara N, Chiba T, Fushiya J, Koike T, Imatani A, Shimosegawa T. Eradication therapy is effective for Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma. Tohoku J Exp Med 2012; 228: 223-227 [PMID: 23076291]
50. Choi YJ, Kim N, Paik JH, Kim JM, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Jung HC. Characteristics of Helicobacter pylori-positive and Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphoma and their influence on clinical outcome. Helicobacter 2013; 18: 197-205 [PMID: 23305046 DOI: 10.1111/hel.12033]
51. Zullo A, Hassan C, Ridola L, De Francesco V, Rossi L, Tomao S, Vaira D, Genta RM. Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review. J Clin Gastroenterol 2013; 47: 824-827 [PMID: 23442842 DOI: 10.1097/MCG.0b013e318286ff72]
52. Raderer M, Wöhrer S, Kiesewetter B, Dolak W, Lagler H, Wotherspoon A, Muellauer L, Chott A. Antibiotic treatment as sole management of Helicobacter pylori-negative gastric MALT lymphoma: a single center experience with prolonged follow-up. Ann Hematol 2015; 94: 969-973 [PMID: 25579756 DOI: 10.1007/s00277-014-2298-3]
53. Govi S, Dognini GP, Licata G, Crocchiolo R, Resti AG, Ponzoni M, Ferreri AJ. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: fnal results of a single-centre phase II trial. Br J Haematol 2010; 150: 226-229 [PMID: 20433679 DOI: 10.1111/j.1365-2141.2010.08179.x]
54. Kiesewetter B, Raderer M. Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature. Blood 2013; 122: 1350-1357 [PMID: 23770778 DOI: 10.1182/blood-2013-02-486522]
55. Kim SW, Lim do H, Ahn YC, Kim WS, Kim SJ, Ko YH, Kim KM. Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 2013; 19: 6062-6068 [PMID: 24106407 DOI: 10.3748/wjg.v19.i36.6062]
56. Zullo A, Hassan C, Andriani A, Cristofari F, Bassanelli C, Spinelli GP, Tomao S, Morini S. Treatment of low-grade gastric MALT-lymphoma unresponsive to Helicobacter pylori therapy: a pooled-data analysis. Med Oncol 2010; 27: 291-295 [PMID: 19308737 DOI: 10.1007/s12032-009-9207-y]
57. Zucca E, Conconi A, Laszlo D, López-Guillermo A, Bouabdallah R, Coiffer B, Sebban C, Jardin F, Vitolo U, Morschhauser F, Pileri SA, Copie-Bergman C, Campo E, Jack A, Floriani I, Johnson P, Martelli M, Cavalli F, Martinelli G, Thieblemont C. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol 2013; 31: 565-572 [PMID: 23295789 DOI: 10.1200/JCO.2011.40.6272]
58. Raderer M, Wohrer S, Streubel B, Drach J, Jager U, Turetschek K, Troch M, Puspok A, Zielinski CC, Chott A. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411-417 [PMID: 17220639 DOI: 10.1159/000098555]
59. Otsuka T, Noda T, Yokoo M, Ibaraki K. Recurrent gastric perforation as a late complication of radiotherapy for mucosa-associated lymphoid tissue lymphoma of the stomach. Intern Med 2008; 47: 1407-1409 [PMID: 18670146]
60. Asano N, Iijima K, Terai S, Uno K, Endo H, Koike T, Iwai W, Iwabuchi T, Hatta W, Abe Y, Imatani A, Shimosegawa T. Signet Ring Cell Gastric Cancer Occurring after Radiation Therapy for Helicobacter pylori-Uninfected Mucosa-Associated Lymphoid Tissue Lymphoma. Case Rep Gastroenterol 2011; 5: 325-329 [PMID: 21712948 DOI: 10.1159/000329559]